Optimal use of sentinel lymph node biopsy versus axillary lymph node dissection in patients with breast carcinoma: A decision analysis

Sandra L. Wong, Troy D. Abell, Celia Chao, Michael J. Edwards, Kelly M. McMasters

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

BACKGROUND. There are no data available from randomized controlled trials that compare the efficacy of sentinel lymph node (SLN) biopsy with Level I/II axillary lymph node dissection (ALND) in patients with breast carcinoma. We performed a formal decision analysis to determine whether SLN biopsy is appropriate, compared with ALND, for patients with T1, T2, and T3 tumors and to quantify the relative value of these two procedures in the management of patients with breast carcinoma. METHODS. All clinically relevant outcomes were modeled for both SLN biopsy and ALND. The probabilities of complications and outcomes were derived using data from the University of Louisville Breast Cancer Sentinel Lymph Node Study and from extensive review of previous studies. Utilities were assigned by the authors, incorporating values from the literature whenever possible. RESULTS. The expected utility of SLN biopsy was higher than the expected utility for ALND for T1 and T2 tumors that were 4.0 cm or smaller. There was no clear preference for either procedure with tumors that were larger than 4.0 cm. The T1 and T2 results were robust to sensitivity analysis. CONCLUSIONS. The results of this decision analysis suggest that SLN biopsy is preferred over. ALND for patients with breast tumors that are 4.0 cm or smaller. Patients should be aware of the potential for false-negative results in SLN biopsy, but this risk is outweighed by the decreased morbidity associated with the procedure itself.

Original languageEnglish (US)
Pages (from-to)478-487
Number of pages10
JournalCancer
Volume95
Issue number3
DOIs
StatePublished - Aug 1 2002
Externally publishedYes

Fingerprint

Sentinel Lymph Node Biopsy
Decision Support Techniques
Lymph Node Excision
Breast Neoplasms
Neoplasms
Randomized Controlled Trials
Morbidity

Keywords

  • Axillary lymph node dissection
  • Breast carcinoma
  • Sentinel lymph node biopsy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Optimal use of sentinel lymph node biopsy versus axillary lymph node dissection in patients with breast carcinoma : A decision analysis. / Wong, Sandra L.; Abell, Troy D.; Chao, Celia; Edwards, Michael J.; McMasters, Kelly M.

In: Cancer, Vol. 95, No. 3, 01.08.2002, p. 478-487.

Research output: Contribution to journalArticle

Wong, Sandra L. ; Abell, Troy D. ; Chao, Celia ; Edwards, Michael J. ; McMasters, Kelly M. / Optimal use of sentinel lymph node biopsy versus axillary lymph node dissection in patients with breast carcinoma : A decision analysis. In: Cancer. 2002 ; Vol. 95, No. 3. pp. 478-487.
@article{bd0622c0d5764e0aae3eea01d40f5a45,
title = "Optimal use of sentinel lymph node biopsy versus axillary lymph node dissection in patients with breast carcinoma: A decision analysis",
abstract = "BACKGROUND. There are no data available from randomized controlled trials that compare the efficacy of sentinel lymph node (SLN) biopsy with Level I/II axillary lymph node dissection (ALND) in patients with breast carcinoma. We performed a formal decision analysis to determine whether SLN biopsy is appropriate, compared with ALND, for patients with T1, T2, and T3 tumors and to quantify the relative value of these two procedures in the management of patients with breast carcinoma. METHODS. All clinically relevant outcomes were modeled for both SLN biopsy and ALND. The probabilities of complications and outcomes were derived using data from the University of Louisville Breast Cancer Sentinel Lymph Node Study and from extensive review of previous studies. Utilities were assigned by the authors, incorporating values from the literature whenever possible. RESULTS. The expected utility of SLN biopsy was higher than the expected utility for ALND for T1 and T2 tumors that were 4.0 cm or smaller. There was no clear preference for either procedure with tumors that were larger than 4.0 cm. The T1 and T2 results were robust to sensitivity analysis. CONCLUSIONS. The results of this decision analysis suggest that SLN biopsy is preferred over. ALND for patients with breast tumors that are 4.0 cm or smaller. Patients should be aware of the potential for false-negative results in SLN biopsy, but this risk is outweighed by the decreased morbidity associated with the procedure itself.",
keywords = "Axillary lymph node dissection, Breast carcinoma, Sentinel lymph node biopsy",
author = "Wong, {Sandra L.} and Abell, {Troy D.} and Celia Chao and Edwards, {Michael J.} and McMasters, {Kelly M.}",
year = "2002",
month = "8",
day = "1",
doi = "10.1002/cncr.10696",
language = "English (US)",
volume = "95",
pages = "478--487",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Optimal use of sentinel lymph node biopsy versus axillary lymph node dissection in patients with breast carcinoma

T2 - A decision analysis

AU - Wong, Sandra L.

AU - Abell, Troy D.

AU - Chao, Celia

AU - Edwards, Michael J.

AU - McMasters, Kelly M.

PY - 2002/8/1

Y1 - 2002/8/1

N2 - BACKGROUND. There are no data available from randomized controlled trials that compare the efficacy of sentinel lymph node (SLN) biopsy with Level I/II axillary lymph node dissection (ALND) in patients with breast carcinoma. We performed a formal decision analysis to determine whether SLN biopsy is appropriate, compared with ALND, for patients with T1, T2, and T3 tumors and to quantify the relative value of these two procedures in the management of patients with breast carcinoma. METHODS. All clinically relevant outcomes were modeled for both SLN biopsy and ALND. The probabilities of complications and outcomes were derived using data from the University of Louisville Breast Cancer Sentinel Lymph Node Study and from extensive review of previous studies. Utilities were assigned by the authors, incorporating values from the literature whenever possible. RESULTS. The expected utility of SLN biopsy was higher than the expected utility for ALND for T1 and T2 tumors that were 4.0 cm or smaller. There was no clear preference for either procedure with tumors that were larger than 4.0 cm. The T1 and T2 results were robust to sensitivity analysis. CONCLUSIONS. The results of this decision analysis suggest that SLN biopsy is preferred over. ALND for patients with breast tumors that are 4.0 cm or smaller. Patients should be aware of the potential for false-negative results in SLN biopsy, but this risk is outweighed by the decreased morbidity associated with the procedure itself.

AB - BACKGROUND. There are no data available from randomized controlled trials that compare the efficacy of sentinel lymph node (SLN) biopsy with Level I/II axillary lymph node dissection (ALND) in patients with breast carcinoma. We performed a formal decision analysis to determine whether SLN biopsy is appropriate, compared with ALND, for patients with T1, T2, and T3 tumors and to quantify the relative value of these two procedures in the management of patients with breast carcinoma. METHODS. All clinically relevant outcomes were modeled for both SLN biopsy and ALND. The probabilities of complications and outcomes were derived using data from the University of Louisville Breast Cancer Sentinel Lymph Node Study and from extensive review of previous studies. Utilities were assigned by the authors, incorporating values from the literature whenever possible. RESULTS. The expected utility of SLN biopsy was higher than the expected utility for ALND for T1 and T2 tumors that were 4.0 cm or smaller. There was no clear preference for either procedure with tumors that were larger than 4.0 cm. The T1 and T2 results were robust to sensitivity analysis. CONCLUSIONS. The results of this decision analysis suggest that SLN biopsy is preferred over. ALND for patients with breast tumors that are 4.0 cm or smaller. Patients should be aware of the potential for false-negative results in SLN biopsy, but this risk is outweighed by the decreased morbidity associated with the procedure itself.

KW - Axillary lymph node dissection

KW - Breast carcinoma

KW - Sentinel lymph node biopsy

UR - http://www.scopus.com/inward/record.url?scp=0036682091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036682091&partnerID=8YFLogxK

U2 - 10.1002/cncr.10696

DO - 10.1002/cncr.10696

M3 - Article

C2 - 12209739

AN - SCOPUS:0036682091

VL - 95

SP - 478

EP - 487

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -